NONOF:OTCMKTS
Novo Nordisk A/S
$39.20
arrow_upward
+0.60%(+0.23) 1D
Oct 21, 12:00:32 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NONOF...
Open
$36.79
High
$39.38
Low
$36.79
Mkt. cap
132.55B
Avg. vol.
136.40K
Volume
2.89K
52-wk high
$64.75
52-wk low
$34.00
Beta
0.63
Shares outstanding
3.39B
No. of employees
67K
Open
$36.79
High
$39.38
Low
$36.79
Mkt. cap
132.55B
Avg. vol.
136.40K
Volume
2.89K
52-wk high
$64.75
52-wk low
$34.00
Beta
0.63
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
AD HOC NEWS
·
2 hours ago
Novo-Nordisk stock: Oddo BHF raises target to DKK 305 for Novo-Nordisk stock
Zacks Investment Research
·
3 hours ago
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
The Motley Fool
·
4 hours ago
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Traders Union
·
8 hours ago
Will Novo Nordisk stock sustain gains amid Wegovy pill approval and strong trial data?
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMike Doustdar
Employees66.7K
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com